Triple Negative Breast Cancer Trial: A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- or known BRCA1 or BRCA2 mutation associated breast cancer.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Docetaxel
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms TNT

Most Recent Events

20 Feb 2019 Biomarkers information updated
25 Dec 2013 Accrual to date is 91% according to United Kingdom Clinical Research Network record.
20 Oct 2013 Accrual to date is 89% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight